Nearly all an ti bi ot ics can cause some form of di arrhoea. Clostridium difficile in fec tion has be come an im por tant area in our daily clin i cal prac tice and is known to cause a broad spec trum of con di tions rang ing from asymp tom atic car riage to the life-threat en ing pseudomembranous co li tis (PMC), with toxic megacolon and ileus. Pa tients most at risk are those who have been treated with broad spectrum an ti bi ot ics, ,those with se ri ous un der ly ing co-morbid i ties and the el derly . Over 80% of Clostridium difficile in fec tion re ported are in peo ple aged over 65 years. Com bi na tion of rapid and ac cu rate di ag no sis will re sult in a better man age ment of Clostridium difficile infec tion. Dis con tinu a tion of caus ative agents such as an tibi otic treat ment is of ten cu ra tive. In more se ri ous cases, oral ad min is tra tion ofmetronidazole or vancomycin is the treat ment of choice.. Pa tients should be treated promptly when the di ag no sis of Clostridium difficile co litis is made to avoid sepsis or bowel per fo ra tion. Re lapses of Clostridium difficile in fec tion have been re ported in about 20-25% of cases, this may in crease to 45-60% after the first re cur rence on. In some cases colectomy may im prove the out come of the pa tient with sys temic in fection or com pli cated Clostridium difficile co li tis. This ar ticle re views the cur rent lit er a ture re gard ing ep i de mi o logi cal pic ture, mi cro bi ol ogy, histopathology and both med i cal and sur gi cal man age ments.
A n ti bi otic as so ci ated di ar rhoea oc curs af ter the consump tion of an ti bi ot ics as a re sult of dis tur bance of the bal ance in the nor mal bac te ria flora of the in di vid ual. Most of the bac te rial flora are com men sals and keep in check the vir u lent bac te ria in the same flora. Once the bal ance is dis turbed then vir u lent bac te ria may pre vail and cause ill ness which is char ac ter ised by any one or com bi na tion of the fol low ing symp toms: wa tery di arrhoea, fe ver, mu cous in stool, nau sea, loss of ap pe tite and in se vere cases bloody di ar rhoea and fea tures of tox aemia.
Nearly all an ti bi ot ics are li a ble to cause di ar rhoea but most com monly are Cephalosporin, Clindamycin, Penicil lins and Fluoroquinolones.
The most se vere form of an ti bi otic as so ci ated di ar rhoea is caused by Clostridium difficile (CD) CD is an an aer o bic, gram pos i tive, spore form ing bacte rium. It is the lead ing cause of hos pi tal-as so ci ated di arrhoea in pa tients re ceiv ing an ti bi otic ther apy and causes sub stan tial mor bid ity and mor tal ity 1 . It has been es timated that a 1/3 rd of hos pi tal as so ci ated di ar rhoea are due to CD in fec tion 2 . CD was de scribed as part of the nor mal flora of the neo na tal gas tro in tes ti nal tract in 1935 3 . It colo nises 40-60% of ne o nates and 1-3% of the lower gas tro in tes ti nal tracts of healthy, asymp tom atic adults. In ci dence of CD colo nis ation in creases to 20-50% in hospi ta lised pa tients and those in long-term healthcare fa cil ities 4 . The crit i cal fac tor in the pathogenesis of CD in fec tion is dis rup tion of the nor mal co lonic microflora caused by broad spec trum antimicrobials and immunosuppressive ther apy. Col o ni za tion of CD gen er ally oc curs through the in ges tion of heat-re sis tant spores, which con vert to veg eta tive forms in the co lon. Risk fac tors for CD in fec tion in clude age over 65 years, sig nif i cant co-mor bid i ties and im mu no de fi ciency 5&6 . One study shows the in ci dence of CD in fec tion is ris ing in pa tients with In flam ma tory Bowel Dis ease (IBD) with a higher in ci dence and case fa tal ity rate in ul cer ative co li tis pa tients than in those with CD, and both sig nif i cantly more than the gen eral pop u la tion 7 Other fac tors con trib ut ing to in creased risk of CD infec tion in clude re cent gas tro in tes ti nal pro ce dures and the pres ence of nasogastric tubes and gas tric acid sup pressants CD causes a broad spec trum of con di tions rang ing from asymp tom atic car riage, through mild or mod er ately severe dis ease with wa tery di ar rhoea, to the life-threat en ing pseudomembranous co li tis (PMC) , with toxic megacolon and ileus. It has been im pli cated as the caus ative or ganism in 10-25% of pa tients with an ti bi otic-as so ci ated di arrhoea, 50-75% of those with an ti bi otic-as so ci ated co li tis, and 90-100% of those with an ti bi otic-as so ci ated PMC [8] . There is ev i dence to sug gest that re strict ing the use of broad-spec trum an ti bi ot ics, spe cif i cally cephalosporins and clindamycin can re duce the in ci dence of CD in fection . The in ci dence and se ver ity of hos pi tal CD in fec tion in USA nearly dou bled from 31 per 100,000 to 61 per 100,000 per year be tween 1996 and 2003 and CD in fection is re spon si ble for 1 in ev ery 1000 hos pi tal ad missions in Eu rope .
A new hypervirulent strain of CD known as PCR ribotype 078 has emerged in the Neth er lands. The hu man and pig iso lates of this ribotype are highly ge net i cally related. The in ci dence of this strain has in creased from 3% to 13% be tween 2005 and 2008, whereas the pro por tion of in fec tions due to the hypervirulent type 027 strain decreased from 27% to 1%. Ribotype 078 af fects more com mu nity as so ci ated youn ger pop u la tions with out any pre dis pos ing fac tors. 9 . The cost to the UK health ser vice in 1996 was es timated to be in ex cess of £4000 per case 10 . At 2009 costs, a 10% re duc tion in in fec tion with 55,000 cases could save 115,500 bed days and £22 mil lion .
In ves ti ga tion of Clostridium difficile In fec tion

Mi cro bi ol ogy
The re sults from lab o ra tory based di ag nos tic tests server only as a di ag nos tic aid and must be seen in conjunc tion with the clin i cal pic ture. There are many in divid u als ex posed to CD who will not be come ill 11 . CD does not gen er ally cause in fec tion in in fants, as the cells of the co lonic mu cosa are too im ma ture to bind the toxin .
The es tab lished guide lines for lab o ra tory di ag no sis of CD in fec tion are ei ther based on bac te rial cul ture or demon stra tion of toxin A and B in a stool sam ple Di rect stool de tec tion as say can be per formed ei ther using cytotoxicity as say or en zyme immunoassay. En zyme immunoassay (EIA), which al lows di rect de tec tion of CD toxin , is the pre ferred di ag nos tic as say and widely used in the most clin i cal lab o ra to ries be cause the tech nique is rel a tively sen si tive (60% to 95%), easy to per form and the re sult can be avail able in as lit tle as 2 hours . It is im por tant to emphasise that a neg a tive EIA re sult does not rule out a di ag no sis of CD in fec tion. EIA kits also suf fer from poor pos i tive pre dic tive val ues as the prev a lence within the pop u la tion be ing tested falls be low 10% .
To day, many lab o ra to ries rely on CD toxin A/B test ing alone de spite the lim its of this ap proach and have abandoned bac te rial cul ture. De tec tion of the CD spe cific enzyme glu ta mate dehydrogenase an ti gen (GDH) may in part re place cul ture tech niques and there fore be an al terna tive to cul ture. The GDH is highly sen si tive which allows re li able ex clu sion of CD with out ad di tional tests if the GDH screen is neg a tive 12 . The dis ad van tage of this test is that will not de ter mine the pres ence of toxin, therefore GDH screen-pos i tive sam ples should be fur ther processed by per form ing toxin A/B test ing such as EIA and those sam ples that are GDH pos i tive but toxin A/B EIA neg a tive may be fur ther tested by us ing Poly mer ase Chain Re ac tion (PCR).
HISTOPATHOLOGY
The af fected co lon may ap pear ex ter nally nor mal but the mu cosa may show a vari able de gree of oe dema, conges tion and ul cer ation with pseudomembrane for ma tion typ i cal of CD in fec tion. Some times the ex ter nal ap pearance does not match the mucosal changes but some times it ap pears con gested, di lated and up to the point of per fora tion.
Finney first de scribed pseudomembranous le sions of the in tes ti nal tract in 1893 13 . In the early 1980's it was im pli cated as fac tor in an ti bi otic-as so ci ated di ar rhoea.
In PMC the co lonic mu cosa be comes ne crotic with the for ma tion of a fibrinous mush room-like exudative membrane con sist ing of mucin, leu co cytes and ep i the lial cells (sum mit le sions). This pseudomembrane is at tached to the mu cosa and is seen as mul ti ple fri a ble yel low and white plaques vary ing in size from a few milli metres up to ap prox i mately 2 centi metres . The plaques co alesce to form larger plaques as the dis ease pro gresses. The mucosa be tween the plaques may show slight hyperaemia and in flam ma tion, or may ap pear nor mal; how ever, the sub mu cosa gen er ally shows an in flam ma tory re ac tion and ne cro sis 14 . Ischemia may show fea tures of PMC.
En dos copy
Most cases with pseudomembranes found on en doscopy will have CD in fec tion 15 . Flex i ble sigmoidoscopy can pro vide an im me di ate di ag no sis in fulminant cases of CD in fec tion , but may fail to de tect up to 10% of cases with out visu ali sa tion of the prox i mal co lon . Colonoscopy is there fore rec om mended in case pseudomembranes are lim ited to the prox i mal co lon, which is in ac ces si ble by sigmoidoscopy 16 . Ab sence of pseudomembranes does not ex clude CD in fec tion, as they are usu ally not seen in mild cases or in pa tients with concom i tant in flam ma tory bowel dis ease. In gen eral, en doscopy should be avoided in pa tients with fulminant co li tis due to the risk of toxic megacolon and co lonic per fo ration.
Other non-spe cific in ves ti ga tions
Plain ab dom i nal ra di og ra phy and com puted to mog raphy (CT) may aid in the de tec tion of co li tis. Pa tients with toxic megacolon and par a lytic ileus may be di ag nosed quickly with the aid of a CT scan
Med i cal man age ment
Al though CD is the ma jor in fec tious cause of an ti biotic-as so ci ated di ar rhoea, it must be dis tin guished from other in fec tious and non-in fec tious causes of di ar rhoea. Other po ten tial patho gens in clude Klebsiella oxytoca, Staph y lo coc cus aureus, Clostridium perfringens, Candida spp. and Sal mo nella . The treat ment of CD infec tion de pends on the clin i cal pre sen ta tion and once the di ag no sis of CD in fec tion has been made, the dis ease should be man aged as a dis ease en tity on its own right .
The man age ment of CDI can be di vided into the follow ing cat e go ries:
Asymp tom atic pa tients
No CD in fec tion treat ment is re quired in asymp tom atic pa tients
Mild to mod er ate dis ease
Pa tients who are clin i cally sta ble and who have no crite ria of se vere dis ease may be man aged con ser va tively by re moval of the caus ing an ti bi otic and fluid re sus ci tation. Such pa tients should be closely mon i tored for signs of de te ri o ra tion. Di ar rhoea can be ex pected to re solve promptly in 15 to 23 per cent of pa tients . Sup port ive care should be given, in clud ing hydration, elec tro lyte bal ance and nu tri tion. Anti-peri stal tic agents should be avoided in acute in fec tion. This is be cause of the the o ret i cal risk of pre cip i tat ing toxic megacolon by slow ing the clear ance of CD toxin from the in tes tine . If spe cific CD in fec tion ther apy is re quired then metronidazole 400mg-500mg orally three times a day for 10-14 days is suit able and as ef fec tive as oral vancomycin in mild to mod er ate CD infec tion.
Se vere dis ease
The UK De part ment of Health Steer ing Group on Healthcare As so ci ated In fec tion rec om mends us ing any of the fol low ing as an in di ca tion of se vere CD in fec tion: WBC >15 X 10/L, acutely ris ing blood creatinine (e.g. >50% in crease above base line), body tem per a ture >38.5°C and ev i dence of se vere co li tis (ab dom i nal signs, ra di ol ogy)
They also rec om mend the use of oral vancomycin in pref er ence to metronidazole in this group of pa tients.
For pa tients with se vere or re frac tory cases of CD infec tion, there is ev i dence that oral vancomycin (125 mg four times per day for 10-14 days) is pref er a ble to metronidazole as metronidazole has a rel a tively high rate of treat ment fail ure and also a slower clin i cal re sponse com pared with oral Vancomycin [ 17] . The ma jor pharma co log i cal ad van tage of vancomycin over metronidazole is that vancomycin is not ab sorbed as readily by the gut so the max i mal ef fect of the vancomycin can act intra-luminally on CD toxin pro duc ers.
A re cent study by Zar et al [18] showed that the cure rate in pa tients treated for se vere CD in fec tion was signif i cantly higher with vancomycin com pared to metronidazole (97% ver sus 76%).
In se vere cases not re spond ing to oral vancomycin (125 mg four times per day), high dose oral Vancomycin (up to 500 mg four times per day if nec es sary ad min is tered via a nasogastric tube) plus in tra ve nous (iv) Metronidazole (500 mg four times per day) are rec ommended 17 . The ad di tion of oral rifampicin (300 mg twice daily) or iv im mu no glob u lin (400 mg/kg) may also be con sid ered. Al though there are no ro bust data to sup port these rec om men da tions, the very poor prog no sis may justify ag gres sive ther apy 17 . Se verely ill pa tients with CD in fec tion may re quire imme di ate sur gi cal at ten tion, par tic u larly if they fail to improve clin i cally or ex hibit signs of ab dom i nal com pli cations. In life-threat en ing sit u a tion, toxic megacolon should be sus pected if the pa tient de vel ops ab dom i nal dis ten sion with less fre quent di ar rhoea; this may re flect par a lytic ileus re sult ing from loss of co lonic mus cu lar tone 17 .
Re cur rent / re laps ing CD in fec tion
Man age ment of re cur rent CD in fec tion re mains con trover sial, al though most re lapses re spond to fur ther courses of an ti bi ot ics that have been given pre vi ously.
20-25% of pa tients with CD in fec tion will go on to develop re laps ing CD in fec tion even with ap pro pri ate treatment . This is usu ally due to ger mi na tion of per sis tent CD spores in the co lon af ter treat ment, gen er ally within 3 to 21 days , or to re-in fec tion be cause of re-in ges tion of the patho gen. One study showed that 50% of re lapses were due to re-in fec tion with a dif fer ent strain rather than re cur rence with the orig i nal strain . The risk of re lapse or re-in fec tion in creases to 40-60% af ter the first re cur rence , and up to 5% of pa tients can have more than six re currences 17 . Re cur rence due to an ti bi otic re sis tant or gan isms is un com mon.
The an ti bi otic ther apy used in the first CD in fec tion recur rence is usu ally the same an ti bi otic that had been initially used un less the in fec tion is se vere .
Surgical management
With the rap idly in creas ing in ci dence of CD in fec tion over the past ten years, the early in volve ment and reg u lar re view of gas tro in tes ti nal sur geons is es sen tial in the man age ment of pa tients with se vere fulminant co li tis.
Even so, mor tal ity rates fol low ing colectomy are in the re gion of 30-60% 17 . An ti bi otic pro phy laxis ad min is tered in the perioperative pe riod has been shown to sig nif i cantly decrease the rate of sur gi cal site in fec tion fol low ing colorectal sur gery 19 . Al though all an ti bi ot ics carry a risk of CD in fec tion, re search has shown that cer tain an ti bi otics such as third-gen er a tion cephalosporins and fluoroquinolones are as so ci ated with a sig nif i cantly higher risk than oth ers . High in ci dences of CD in fec tion have also been de scribed fol low ing other types of gas troin tes ti nal and vas cu lar sur gery 17 .
In di ca tions for sur gery
Al though fre quently de vel oped dur ing a hos pi tal iza tion and of ten af ter a sur gi cal pro ce dure, CD in fec tion may de velop out side of a hos pi tal set ting. Di ar rhea may be absent and stool sam ples may be neg a tive for CD toxin. There is ev i dence to sug gest that ab dom i nal com puted tomog ra phy of fers a higher de gree of sen si tiv ity in di agnos ing PMC , al though it is not ef fec tive at pre dict ing the need for sur gi cal in ter ven tion . Rapid immunoassays may al low for pre op er a tive con fir ma tion of the cause of severe co li tis where sur gery can not wait un til cul ture results are avail able.
To de crease mor bid ity and mor tal ity in pa tients in partic u larly in high risk groups such as the el derly or immunocompromised with acute se vere co li tis, an early sur gi cal in ter ven tion should be con sid ered af ter a joint de ci sion be tween med i cal and sur gi cal gastroenterologists.
Ev i dence from large-scale stud ies to as sist in guid ing sur gi cal man age ment of these pa tients is lack ing. There are no pub lished ran dom ized con trolled tri als eval u at ing the role of sur gery in man ag ing PMC. In a small, ret rospec tive study by Koss et al in volv ing 14 pa tients, in dica tions for sur gery were given as sys temic tox ic ity and peri to ni tis, ra dio log i cal and clin i cal ev i dence of pro gressive toxic co lonic di la ta tion and bowel per fo ra tion [20] . In a fur ther re port pub lished by Synnott et al, in di ca tions for op er a tion were sys temic tox ic ity with py rexia, marked leucocytosis and ab dom i nal signs lead ing to progres sive or gan fail ure, de spite ap pro pri ate anticlostridial an ti bi otic ther apy 21 . Ba si cally, fulminant form of PMC is the only con di tion that can di dates the pa tient for sur gi cal treat ment. This is the case in 3-8% of pa tients 22 . The real chal lenge in sur gi cal treat ment of PMC is the ques tion when to op er ate, and when can we state that colectomy un der such dif fi cult cir cum stances ac tu ally reduces pa tient mor tal ity or whether it does more dam age in such se verely ill pa tients.
All other out come mea sures in such dif fi cult pa tients are ac tu ally of no clin i cal im por tance. An ex cel lent systemic re view by Stew art et all 23 pre sented re sults of colectomy in cases of fuminant PMC. Au thors con cluded that a pa tient with fulminant form of PMC, whose disease has pro gressed to the point of a life-threat en ing infec tion de spite all avail able non sur gi cal ther apy, colectomy pro vides a mor tal ity ben e fit com pared with on go ing med i cal ther apy (Fig ure 1.) On the other hand, we should al ways be care ful and should n't of fer sur gi cal treat ment to ev ery pa tient, regard less of ones comorbidities. Also in men tioned systemic re view not in all stud ies in cluded, pa tient bene fited from sur gi cal treat ment. An other very im por tant is sue that is still to be an swered is tim ing for sur gi cal treatment. Of fered too early sur gery can have very fa vor able re sults, and if we wait too long, op er a tion can be deemed un nec es sary, be cause fa tal out come is in ev i ta ble in ev ery way.
Sur gi cal pro ce dures
In the study by Koss et al, the 9 pa tients who un derwent to tal colectomy had a mor tal ity rate of 11.1% compared with 100% in the 4 pa tients who un der went left hemicolectomy. One pa tient who un der went right hemicolectomy sur vived af ter a pro longed hos pi tal stay 20 . In their study of 13 pa tients who un der went colectomy for PMC, Lipsett et al found that all 4 pa tients who un derwent seg men tal colectomy died com pared with 14% of the re main der who had a sub to tal colectomy 24 . The authors emphasise that the ex ter nal ap pear ance of the co lon may be de cep tively nor mal de spite se vere mucosal disease, and this should not in flu ence the de ci sion to resect the en tire co lon. In the larg est re ported se ries of 73 CD in fec tion pa tients un der go ing colectomy, the mor tal ity rates of pa tients who un der went seg men tal (n=10) or subto tal (n=63) colectomy was (10% vs. 38%, re spec tively 25 . A less in va sive yet equally ef fec tive so lu tion has recently been sug gested -a di vert ing loop ileostomy with co lonic la vage as an al ter na tive to colectomy. Neal et al. 26 pub lished the re sults for 42 pa tients with fulminant PMC who un der went a di vert ing loop ileostomy, with poly eth yl ene gly col and vancomycin co lonic la vage through the ef fer ent limb. Again, the ques tion when to op er ate re mained un an swered. Also in some pa tients colectomy was per formed af ter di vert ing ileostomy. There is al ways the dan ger of re cur rent co li tis af ter ileostomy clo sure, as well as the case of re sis tant types of C. difficile, where la vage agents hav no real ef fect.
Prog nos tic fac tors fol low ing sur gi cal in ter ven tion
A ret ro spec tive study by Pepin et al of 130 pa tients under go ing sur gery with sim i lar in di ca tions to those described above con cluded that 30-day mor tal ity in creased with in creas ing age (but not co-morbiditiy), and cor related with raised pre op er a tive lac tate, leucocytosis, reduced al bu min and re nal fail ure. On multivariate anal ysis, 75% of pa tients with a pre op er a tive leucocytosis = 50.0 x10 9 /L or lac tate =5.0 mmol/L died 27 . One of rea sons for very high mor tal ity fol low ing surgery is de lay in sur gery.
It is in ter est ing to note that the oc ca sional case of CD in fec tion af fect ing the il eum af ter sub to tal colectomy 28 .
SUMMARY TRETMAN ODNOSA ANTIBIOTIKA I CLOSTRIDIUM DIFFICILE
Skoro svi antibiotici mogu izazvati odreðeni stepen dijareje. Infekcija sa Clostridium difficile je postala znaèajni deo naša svakodnevne klinièke prakse i uzroènik je mnogih problema, od asimptomatskih kliconoša do po život opasnog pseudomembranoznog kolitisa sa toksiènim megakolonom i ileusom. Najrizièniji su bolesnici leèeni antibioticima širokog spektra, sa ozbiljnim udruženim ko-morbiditetom i starije osobe. Preko 80% infekcija sa Cl. difficile se javlja kod osoba starijih od 65 godina.
Kombinacija brze i taène dijagnoze aee rezultirati boljim leèenjem infekcije sa Cl. difficile.
Iskljuèenje uzroènika, kao što je antibiotska terapija je èesto efikasno. U težim sluèajevima metoda izbora je oralna primena Metronidazola ili Vancomicina.
Bolsnike sa kolitisom izazvanim Cl. difficile treba urgentno tretirati da bi se izbegla sepsa ili perforacija creva.
Saopšteno je da se relaps infekcije zbog Cl. difficile javlja u oko 20-25% sluèajeva a može da naraste i do 45-60% posle prvog recidiva bolesti.
U izvesnim sluèajevima kolostoma može poboljšati ishod leèenja bolesnika sa sistemskom infekcijom ili komplikacijama kolitisa izazvanog Cl. difficile.
Ovaj èlanak predstavlja revijalni prikaz savremene litrerature koja se odnosi na epidemiološku sliku, mikrobiologiju, histopatologiju i medikamentno i hirurško leèenje.
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